Ubrogepant users' real‐world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
Ubrogepant demonstrated real-world effectiveness in the acute treatment of migraine, as evidenced by high levels of treatment satisfaction and a strong indication of their intent to continue using the medication.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Anand R. Shewale (ORCID: https://orcid.org/0000-0002-3138-5623)
- Ali Ezzati (ORCID: https://orcid.org/0000-0003-1307-4589)
- Shivaji Manthena
- Weijie Poh (ORCID: https://orcid.org/0000-0002-9700-3237)
- Kate Burslem
- Michael L. Reed (ORCID: https://orcid.org/0000-0002-1353-2300)
- François Cadiou
- Jinjie Liu (ORCID: https://orcid.org/0000-0002-5922-8216)
Institutions
- Albert Einstein College of Medicine (US)
- University of California, Irvine (US)
- AbbVie (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/head.14839
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- AbbVie